Acelrx Pharmaceuticals (ACRX) 4.58 $ACRX Insider Trading

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 1:32 PM

Acelrx Pharmaceuticals (ACRX) 4.58 $ACRX

Insider Trading Alert - STFC, ACRX And CSC Traded By Insiders
at The Street - Fri Apr 24, 9:30AM CDT
Stocks with insider trader activity include STFC, ACRX and CSC
ACRX: 4.58 (-0.16), STFC: 23.91 (unch), CSC: 65.56 (-0.09)

AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting
PR Newswire - Tue Apr 14, 6:00AM CDT
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting to be held April 15th to April 18th, 2015 at the Gaylord Opryland Resort and Convention Center in Nashville, TN. SAGES 2015 will continue a long-standing tradition of strong didactic sessions by world-renowned experts, combined with exploration of innovative technology. The meeting will bring together Gastrointestinal and Endoscopic surgeons representing over 70 different countries.
ACRX: 4.58 (-0.16)

AcelRx Pharmaceuticals, Inc. Former Employees With Information Concerning Zalviso System Dispensing Errors are Encouraged to Contact Brower Piven -- ACRX
GlobeNewswire - Wed Apr 08, 5:25PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation encourages former employees of AcelRx Pharmaceuticals, Inc. ("AcelRx"

(Nasdaq:ACRX) with information relating to the issues raised in the U.S. Food and Drug Administration's July 25, 2014 Complete Response Letter regarding AcelRx's new drug application for Zalviso, including information relating to the incidence of optical system errors and dispensing errors by the Zalviso System, a needle-free, handheld, patient-administered, pain management system, to contact Brower Piven either by email at trepetin@browerpiven.com or by telephone at (410) 332-0030.
ACRX: 4.58 (-0.16)

A New Drug In The Works, A New CEO, And A New Delay For AcelRx Pharmaceuticals
Jason Orestes - at Seeking Alpha - Tue Mar 31, 2:18AM CDT

ACRX: 4.58 (-0.16)

AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?
at The Street - Mon Mar 23, 11:15AM CDT
AcelRx shareholders were burned yet again when the company announced new clinical trials were required for its flagship drug. What's to come for this struggling biotech company?
ACRX: 4.58 (-0.16)

AcelRx reports Day 120 List of Questions for Zalviso MAA received by Europe's CHMP
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 10:31AM CDT

ACRX: 4.58 (-0.16)

AcelRx names Howard B. Rosen as interim CEO
M2 - Mon Mar 23, 6:06AM CDT
Pharmaceutical company AcelRx Pharmaceuticals (NasdaqGM:ACRX) disclosed on Friday the addition of Howard B. Rosen as interim chief executive officer with effect from 1 April 12015.
ACRX: 4.58 (-0.16), GILD: 103.69 (-1.52)

AcelRx names interim CEO; cuts 36% of workforce
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 3:25PM CDT

ACRX: 4.58 (-0.16)

AcelRx Appoints Howard B. Rosen as Interim CEO
PR Newswire - Fri Mar 20, 2:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Howard B. Rosen as interim Chief Executive Officer of AcelRx, effective April 1, 2015. Mr. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences and ALZA Corporation. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.
ACRX: 4.58 (-0.16), GILD: 103.69 (-1.52)

AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 1:00PM CDT
AcelRx Pharmaceuticals, Inc. (ACRX) commenced a phase III study on ARX-04 for the treatment of moderate-to-severe acute pain following ambulatory abdominal surgery.
ACRX: 4.58 (-0.16), CYTK: 7.25 (-0.18), LCI: 67.40 (unch), HSP: 87.61 (-0.05)

AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
PR Newswire - Mon Mar 16, 6:00AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. ARX-04 is a non-invasive, single-use 30 mcg sufentanil sublingual tablet in a disposable, pre-filled, single-dose applicator (SDA).
ACRX: 4.58 (-0.16)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm
PR Newswire - Fri Mar 13, 5:26PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"

(NasdaqGM: ACRX).
ACRX: 4.58 (-0.16)

Why AcelRx Pharmaceuticals Inc. Is Crashing
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 10, 12:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What's happening: Shares in AcelRx...
ACRX: 4.58 (-0.16)

AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades
at The Street - Tue Mar 10, 11:21AM CDT
Shares of AcelRx Pharmaceuticals (ACRX) are extending losses as Jefferies downgraded the company to 'hold' from 'buy.'
ACRX: 4.58 (-0.16)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 8:19AM CDT

ACRX: 4.58 (-0.16), RMGN: 1.61 (+0.09), AKRX: 55.24 (-0.68), CS: 26.16 (-0.48), ADHD: 5.90 (+0.07), CTIC: 1.96 (+0.01), ROSE: 22.13 (-0.16), URBN: 41.90 (-0.49), WPRT: 4.46 (unch), UNFI: 70.76 (+0.06), CPE: 8.82 (+0.08), XOXO: 17.50 (-0.28), CLMT: 27.83 (+0.14)

AcelRx Pharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 7:40AM CDT

ACRX: 4.58 (-0.16)

Market Maker Surveillance Report. MOBI, LL, MERU, AXN, BITA, ACRX, Losing Stocks With Lowest Price Friction For Monday, March 9th 2015
M2 - Tue Mar 10, 4:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5134 companies with "abnormal" market making, 3198 companies with positive Friction Factors and 3279 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Sky-mobi Ltd (NASDAQ:MOBI), Lumber Liquidators Holdings Inc (NYSE:LL), Meru Networks Inc (NASDAQ:MERU), Aoxing Pharmaceutical Company Inc (NYSE:AXN), Bitauto Holdings Ltd (NYSE:BITA), AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ACRX: 4.58 (-0.16), AXN: 1.71 (+0.02), LL: 33.07 (-0.58), MOBI: 5.17 (+0.42), BITA: 61.63 (+2.86), MERU: 1.25 (-0.03)

AcelRx Pharmaceuticals' (ACRX) CEO Richard King on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 09, 10:10PM CDT

ACRX: 4.58 (-0.16)

AcelRx Pharmaceuticals misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:10PM CDT

ACRX: 4.58 (-0.16)

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Mon Mar 09, 3:05PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported financial results for the three and twelve months ended December 31, 2014.
ACRX: 4.58 (-0.16)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigo Energy Faces Class Action: Investor Implications

Ah, here we go again, folks. Another day, another stock horror story. This time it’s Tigo Energy, Inc. (NASDAQ:TYGO) struggling under the microscope of a securities class action, care of the Law Offices of Howard G. Smith. If you’ve been keeping an eye on this one, buckle up—it's quite the mess. The Situation at Tigo Energy First off, let’s talk numbers. Tigo...

SHOPLINE's Pitch Day: 14 Brands in the Spotlight

SHOPLINE's Los Angeles Event Highlights Emerging Brands Flip the calendar back to October 1, and you'll find me soaking in the scene at the sprawling halls of SHOPLINE and Plug and Play’s latest event. This wasn’t your run-of-the-mill networking affair; it was a caffeine-fueled, adrenaline-pumping showcase of 14 up-and-coming consumer brands. Now, if there's one thing...

Africa-Caribbean Trade Potential: A $1.65B Opportunity

Untapped Opportunities Between Africa and the Caribbean Who's ready to shake up the trade game between Africa and the Caribbean? According to a fresh-off-the-press report from the International Trade Centre (ITC) and Afreximbank, we could be looking at a whopping $1.65 billion in annual trade between these two regions by 2030. That's right, a billion with a 'B'. But let...

Camtek Hits Record Q3 Revenue; Strong Growth Ahead

Camtek's Record Performance in Q3 2026 Diving straight into the numbers, Camtek (NASDAQ:CAMT) just posted a staggering $161.3 million in Q3 2026 revenues, marking a 21% jump from the previous quarter. Now, that kind of growth isn't just impressive; it's a wake-up call to any investor still snoozing on semiconductor stocks. They're looking at revenues of around $180...

Cerillion 26.2: New AI Powers & Open Standards Edge

Leading the Charge in Telecom AI Ah, the telecom game—it's a battlefield and Cerillion’s just lobbed a game-changer onto the field with their 26.2 release. This ain’t your run-of-the-mill update; we're talking expanded agentic AI capabilities that are set to shake the very core of BSS/OSS solutions. AI Innovations That Matter No fluff here, just solid improvements....

UltraClear Laser Shakes Up Skin Resurfacing Market

Laser Tech Advancing Skin Resurfacing Do you smell that? It's the scent of innovation, wafting through the American Society for Dermatologic Surgery Annual Meeting in San Diego. Acclaro Medical is stealing the limelight with its UltraClear®, a 2910 nm cold fiber laser, redefining the boundaries of skin resurfacing. This little marvel promises to carve out a fresh...

Tom Doyle Takes Helm at Gallagher's HR Consulting

Leadership Shifts in Gallagher's Upper Echelons What a shake-up at Arthur J. Gallagher & Co.! The power torch is officially passing over in its Benefits & HR Consulting Division. Come January 1, 2027, Tom Doyle is strapping in as the new CEO, taking over from William F. "Bill" Ziebell. Now, don't get too teary-eyed—Ziebell's not vanishing into thin air. Instead, he's...

New CMO Joins ARTHEx: Boosting Innovative RNA Focus

ARTHEx Biotech's Strategic Expansion Looks like ARTHEx Biotech is shaking things up with some strategic moves by bringing in Dr. Christian Freitag as their new Chief Medical Officer. Now, if you’re knee-deep in the biotech game, you'll know that having someone like Freitag onboard is akin to adding a star player to your lineup. The guy's got more than two decades of...

CALLAHEAD Unveils AQUA MOVER: Revolutionizing Freshwater Tanks

CALLAHEAD: Bringing Storms to Water Tanks Fresh to the party in the portable sanitation sector is the AQUA MOVER™ from CALLAHEAD. Now, this ain't your everyday contraption. Charles W. Howard, the mastermind and big cheese behind CALLAHEAD, has rolled out what seems like a microscopic hurricane for water tanks—a solution to tackle the old enemy: stagnation. What Makes...

Laser Weapon Market to Double: Military Demand Surges

Pew Pew: Lasers Are the Future of Defense Forget lightsabers, we've got something even flashier—a market that's going to double in worth by 2035. High-energy laser weapons are coming in hot, growing from USD 2.17 billion in 2026 to an estimated USD 4.54 billion by the end of 2035. That's no small potatoes! What's Driving This Beam Dream? The military is all about upping...